CYP19A1 and breast cancer: As aromatase inhibition is widely used to treat ER-positive tumors and AR profiling is part of cutting-edge approaches in breast cancer, the implications of a possible androgen-APRIL/BAFF-pluripotency enhancement might be of significant clinical value in providing a beneficial personalized therapy to patients.